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Discovery and characterization of the cytokine receptor-cytokine-decoy receptor triad
formed by receptor activator of nuclear factor kappa-B ligand (RANKL)–receptor activa-
tor of NF-κB (RANK)–osteoprotegerin (OPG) have led not only to immense advances in
understanding the biology of bone homeostasis, but have also crystalized appreciation
of the critical regulatory relationship that exists between bone and immunity, resulting
in the emergence of the burgeoning field of osteoimmunology. RANKL–RANK–OPG are
members of the tumor necrosis factor (TNF) andTNF receptor superfamilies, and share sig-
naling characteristics common to many members of each. Developmentally regulated and
cell-type specific expression patterns of each of these factors have revealed key regulatory
functions for RANKL–RANK–OPG in bone homeostasis, organogenesis, immune tolerance,
and cancer. Successful efforts at designing and developing therapeutic agents targeting
RANKL–RANK–OPG have been undertaken for osteoporosis, and additional efforts are
underway for other conditions. In this review, we will summarize the basic biology of the
RANKL–RANK–OPG system, relate its cell-type specific functions to system-wide mecha-
nisms of development and homeostasis, and highlight emerging areas of interest for this
cytokine group.
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INTRODUCTION
Functional diversity typifies the cytokines and receptors of the
tumor necrosis factor (TNF) and tumor necrosis factor recep-
tor (TNFR) superfamilies. TNF superfamily (TNFSF) members
are broadly expressed in a variety of tissues and organ systems,
and are commonly associated with expression on cells of the
immune system. In recent years, studies of TNF/TNFR super-
family members have been responsible for elucidating previously
unrecognized linkages between the immune system and other
biological systems, as well as previously unrealized networks con-
trolling various disease conditions (1, 2). An important example
is the system consisting of the cytokine receptor activator of
nuclear factor kappa-B ligand [RANKL; additionally identified as
TNF-related activation-induced cytokine (TRANCE), osteoclast
differentiation factor (ODF), and TNFSF11], its signaling recep-
tor receptor activator of NF-κB (RANK), and the soluble decoy
receptor osteoprotegerin (OPG). The RANKL–RANK–OPG sys-
tem was originally discovered through parallel efforts in the late
1990s that identified it as important to immunity, primarily via
actions on dendritic cells (DCs) (3, 4), and as important to bone
homeostasis through regulation of osteoclasts (OCs) (5, 6). Work
employing various genetically deficient mouse models has shown
the critical role of the RANKL–RANK–OPG system plays in bone
and immunity – significantly contributing to the emergence of the
field of osteoimmunology – as well as organogenesis, and disease
conditions including cancer and rheumatoid arthritis (RA). In this
review, we will provide a summary of current understanding of the
biological functions of the RANKL–RANK–OPG system in devel-
opment, homeostasis, immunity, and disease, as well as ongoing
efforts to target RANKL–RANK–OPG to prevent or fight diseases
like osteoporosis and cancer.
RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-B
LIGAND
Receptor activator of nuclear factor kappa-B ligand (3), which was
independently discovered by four groups, is alternatively named
TRANCE (4), ODF (6), osteoprotegerin ligand (OPGL) (5), and
designated TNFSF11. The gene encoding the RANKL protein,
Tnfsf11, is located on human chromosome 13q14, and a con-
served syntenic region on mouse chromosome 14 (4). RANKL
protein is a type II membrane protein bearing close homology to
TNFSF members TRAIL, FasL, and TNF-a (4). Full-length murine
RANKL is 316 amino acids, shares 83% sequence homology with
human RANKL (4), and consists of a C-terminal extra-cellular
receptor-interacting domain and a transmembrane domain, but
is found in both membrane-bound and soluble forms (7). Cleav-
age of soluble RANKL from the membrane-embedded portion
is mediated by the metalloprotease–disintegrin TNF-a convertase
(TACE) (8, 9). Further, three distinct isoforms of RANKL message
have been identified, the shortest of which – lacking the intracellu-
lar and transmembrane domains – may have inhibitory function
(10). These data comport with observations that soluble RANKL is
less efficient at mediating osteoclastogenesis (11). RANKL expres-
sion has been detected in various tissues including T lymphocytes
(4), osteoblasts (OBs), osteocytes and bone stroma, and lung (5, 6,
12, 13). Throughout development RANKL mRNA can be detected
in the brain, heart, kidneys, skeletal muscle, and skin of mouse
embryos, and has been specifically identified in E15 chondrocytes
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(5, 12). Expression of RANKL is highly inducible, and is regulated
by various osteoactive factors including glucocorticoids (14), Vit-
amin D3 [1,25(OH)2D3] (6, 15), IL-1 (16), TNF-a (16), TGF-b
(17), Wnt ligands (18), and LPS (19). Binding studies show that
RANKL can bind to both the functional receptor RANK and the
decoy receptor OPG (3, 5).
RECEPTOR ACTIVATOR OF NF-κB
Receptor activator of NF-κB [(3); alternatively identified as TNF-
related activation-induced cytokine receptor (TRANCE-R) (20)
or osteoclast differentiation and activation receptor (ODAR) (21)]
is the signaling receptor for RANKL. RANK has been designated
TNFRSF11A, and is a type I 616 amino acid homo-trimerizing
transmembrane protein containing four extra-cellular cysteine-
rich pseudorepeats. Trimerization is promoted by interaction with
RANKL (22). The human gene that encodes RANK, Tnfrsf11a,
is located on chromosome 18q22.1 (3), and RANK message is
detected in thymus, liver, colon, mammary glands, prostate, pan-
creas, bone marrow, heart, lung, brain, skeletal muscle, kidney,
liver, and skin (3, 7, 23). RANK is strongly induced, especially on
OC precursor cells, by M-CSF (24). Typical of TNFRSF members,
RANK lacks intrinsic kinase activity and must rely on recruit-
ing factors capable of activating downstream signaling pathways
(summarized in Figure 1). As such, RANK intracellular signal
transduction is mediated first through direct interaction with
tumor necrosis factor receptor-associated factors (TRAFs), which
are recruited upon receptor activation (25, 26). RANK interacts
with TRAFs 1, 2, 3, 5 in a membrane-distal region of the 383 amino
acid cytoplasmic tail, and with TRAF6 at a distinct membrane-
proximal Pro-X-Glu-X-X-(aromatic/acid residue) binding motif
(25–27). TRAF6 is critical activating mitogen-activated protein
kinases (MAPKs) p38 and JNK, as well as the canonical NF-κB
pathway in response to RANK signaling (8, 28, 29). TRAF6 uti-
lizes the adapter TAB2 to interact with the MAPK kinase TAK1 to
mediate RANK signaling (30). While RANK binds similar TRAFs
as the related receptor CD40, it has been shown that stronger
activation of TRAF6 may account for unique RANK function
(31). Other interacting factors that may modulate RANK signaling
include Grb2-associated binding protein 2 (Gab2) (32), epidermal
growth factor receptor (EGFR) (33), four-and-a-half LIM domain
2 (FHL2) (34), Lyn (35), CYLD de-ubiquitinase (36), and TRAF
family member-associated NF-κB activator (TANK) (37). It has
been shown that RANK signaling can regulate calcium oscillation
through downstream activation of regulator of G-protein signal-
ing 10 (RGS10) (38), and that RANK-mediated calcium flux is
itself regulated by transmembrane protein 64 (TMEM64) interac-
tion with sarcoplasmic endoplasmic reticulum Ca(2+) ATPase 2
(SERCA2) (39). RANK also activates Src family kinase signaling
in a manner that leads to Akt/PKB activation through interactions
between TRAF6 and Cbl scaffolding proteins (40, 41). TRAF6-
dependent RANK signaling has been shown to be negatively reg-
ulated via cross-talk with the IFN-g signaling pathway, employing
a mechanism leading to TRAF6 ubiquitination and degradation
(42). More recently, it has been shown that TRAF3 plays a key role
in negatively regulating RANK-mediated activation of the non-
canonical NF-κB pathway (43). One of the signaling properties of
RANK that may distinguish it functionally from some other TNFR
FIGURE 1 | RANK signaling pathways. The RANK receptor lacks intrinsic
enzymatic activity and therefore utilizes interaction with adaptor and
docking proteins, including TRAFs 2, 3, 5, and 6, Gab2, and Cbl to activate
downstream signaling. Gab2 and Cbl are associated with RANK-mediated
activation of c-Src, PI3 kinase (PI3K), and Akt, while TRAFs 2 and 6 can
activate the TAB1/TAB2/TAK1 complex, which (along with other upstream
kinases) leads to activation of IKKβ and MAP kinases (MAPK). Activation of
these pathways promotes translocation and activation of transcription
factors including NFATc1, CREB, NFκB, AP-1, and MITF. Specific
RANK-activated gene transcription varies depending on cell-type, but often
involves feed forward expression of NFATc1, c-fos, and NFκB-related
genes. RANK-associated TRAF3 has been implicated in negative regulation
of the non-canonical NFκB2 pathway through regulation of the upstream
kinase NIK. Inhibition of NIK is mediated by the TRAF3 RING finger domain,
and is overcome when RANK activation by RANKL triggers
autophagic/lysosomal degradation of TRAF3. While many of these
mechanisms may be generalizable to various RANK-expressing cell-types,
some mechanisms appear thus far to be osteoclast (OC) lineage-specific.
The best characterized of these OC-associated mechanisms involves
synergistic signaling between RANK and ITAM motif-containing proteins
DAP12 and FcRγ (which associate with cell surface receptors OSCAR,
PIR-A, or TREM-2) to activate the Syk-PLCγ pathway and flux calcium. This
activity enhances NFATc1 and CREB activities. Synergy with RANK occurs
via coordinate activation of Btk/Tec. RANK further regulates calcium flux in
OC lineage cells by a mechanism involving transmembrane protein 64
(TMEM64) interaction with the sarcoplasmic endoplasmic reticulum Ca(2+)
ATPase 2 (SERCA2). This mechanism further promotes CREB and NFATc1
activity.
superfamily members is its capacity to activate both the canonical
and non-canonical NF-κB pathways. At the level of gene regula-
tion, RANK signaling is crucial for induction of the transcription
factors c-fos and NFATc1/NFAT2 (44–46). The functional effects
of RANK signal transduction are discussed further below.
OSTEOPROTEGERIN
Osteoprotegerin, now designated as TNFRSF11B, was first identi-
fied through a discovery effort targeting TNFRSF homologs in rat,
and human and mouse OPG homologs subsequently identified
exhibited >85% homology (47). Independently discovered and
alternatively named osteoclastogenesis inhibitory factor (OCIF)
(48), TR1 (49), and follicular DC-derived receptor-1 (FDCR-1)
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(50) were found to be identical to OPG. OPG mRNA is detected
in the calavaria, skin, liver, lung, and heart of the adult mouse,
and peaks at days 7 and 15 in fetal tissue (47). OPG is expressed
primarily by bone marrow stromal cells, but can be induced in
B lymphocytes, DCs, and follicular DCs (50). OPG expression
regulated both positively (e.g., TGF-b, IL-1, TNF, estrogen, and
Wnt ligands) and negatively (e.g., prostaglandin E2 (PGE2) and
glucocorticoids) by a wide array of factors, most of which are
associated with bone homeostasis (51). Full-length OPG protein
is 401 amino acids long, which is signal peptidase-cleaved to a
380 amino acid form containing four cysteine-rich N-terminal
domains (domains 1–4), two death domain homologous regions
(domains 5 and 6), and a C-terminal heparin-binding domain
(domain 7) (52, 53), and then N-linked glycosylated, and secreted
as a disulfide-linked homodimer (47–49). As such, OPG is believed
to function primarily as a decoy receptor, modulating interactions
between ligands and signaling receptors. The high-affinity binding
partner for OPG appears to be RANKL, but it has also been shown
to bind with low affinity (3.0 nM at 4°C and 400 nM at 37°C) to
the TNFSF member and pro-apoptotic factor, TRAIL (54). In vitro
and pre-clinical studies suggest that OPG–TRAIL interactions may
be relevant to apoptosis of tumor cells (52). Additional potentially
physiologically relevant ligands of OPG include syndecan-1, gly-
cosaminoglycans (GAGs), von Willebrand Factor, and Factor VIII
von Willebrand Factor complex (52).
ORGANOGENESIS
Receptor activator of nuclear factor kappa-B ligand–receptor acti-
vator of NF-κB has emerged as a critical signaling pathway for
the cellular differentiation and development of epithelial tissues
in various organs. These RANK-dependent processes have impor-
tant implications not only for development, but also for regulating
immunity and cancer.
LYMPH NODES
Characterization of RANKL- and RANK-deficient mice revealed
failed or abnormal development of secondary lymphoid tissues,
including lymph nodes, Peyer’s patches, cryptopatches, and spleen
(55–58). During embryogenesis, secondary lymphoid tissue devel-
opment occurs as RANKL signals through RANK on lymphoid
tissue inducer (LTi) cells recruited to a rudimentary anlage com-
posed of lymphoid tissue organizer (LTo) progenitor cells. LTi cells
then transmit lymphotoxin a/b (LTa/b) to LTo progenitors that
express LTbR, which drives development of mature LTo cells. This
event triggers a feedback loop of RANKL and RANK expression
by mature LTo cells, which amplifies LTi growth and tissue organi-
zation (59). The relevant RANK signaling in this context appears
to be mediated by the transcriptional regulator Id2 (60).
MAMMARY GLANDS
Receptor activator of nuclear factor kappa-B ligand- and RANK-
deficient mice also exhibit defective mammary gland development
(61, 62), which requires RANK-triggered activation of the IKK-
alpha kinase domain in order to activate the non-canonical NF-κB
pathway (63). RANK signaling in the context of mammary gland
development is also associated with expression of cyclin D1, Id2,
and Id4 (59). It has recently been shown that RANK signal-
ing is required for mammary epithelial stem cell activation (64,
65). Further, RANK signaling has been shown to be required for
progesterone-driven proliferation of normal breast tissue (66).
medullary thymic epithelial cells
A critical role for RANKL–RANK signaling has been established
in thymic organ development, and specifically for the epithelial
lineage cells required for negative selection of developing T cells
(67, 68). The thymus educates self-tolerant T cells by eliminating
those expressing potentially self-reactive TCRs and by generating
the immunosuppressive T cells that are essential for prevent-
ing autoimmune disease. Epithelial cells localized in the thymic
medulla called medullary thymic epithelial cells (mTECs) are non-
hematopoietic in origin and are essential for negative selection
(68). Recent studies have revealed that mTECs also contribute to
the selection and survival of immunosuppressive Foxp3-positive
regulatory T cells (Tregs) (68, 69). The significant decrease in
mTECs in the absence of RANKL provision by thymocytes sug-
gests that mTEC differentiation is actually driven by the cells
that mature mTECs subject to negative selection (68). In fact,
this process appears to be initiated in the neo-natal period by
innate RANKL-expressing gamma-delta lineage cells before the
appearance of alpha-beta cells in the thymus (70). mTECs require
signaling through each of the TNFRSF members LTbR, CD40,
and RANK in order to induce sufficient expression of the critical
factors autoimmune regulator (Aire) and tissue-specific antigens
(TSAs), but it had been unclear whether downstream activation
by those receptors was qualitatively or quantitatively distinct. Cell-
specific deletion of the non-canonical NF-κB inhibitor TRAF3
suggests that LTbR and CD40 are similar in their provision of
non-canonical NF-κB activation, but that RANK apparently pro-
vides additional requisite signals during mTEC development (71).
From genetic experiments, however, it is known that the rele-
vant RANK signals are transduced by TRAF6 (67). Together, these
data show that RANK-mediated signaling is required for devel-
opmental processes that critically affect immune regulation and
homeostasis.
M CELLS
Microfold cells are specialized intestinal epithelial-derived cells
that make up roughly 10% of the follicle-associated epithelial
(FAE) cells covering the gut-associated lymphoid tissues (GALT).
Microfold (M) cells exhibit some morphological distinctions com-
pared to neighboring enterocytes, but are most important for their
enhanced capacity for phagocytosis and transcytosis of macromol-
ecules, particulate antigens, and micro-organisms residing in the
gut lumen (9). M cells are essential for transfer of antigens from
orally acquired pathogens, such as Salmonella Typhimurium, to
antigen-presenting cells, and subsequently, for optimal immune
responses (9). Because of their importance to mucosal immu-
nity, various efforts have aimed at determining the mechanisms
of differentiation of M cells. Within the villous crypts of the FAE
reside leucine-rich repeat-containing G-protein-coupled receptor-
(Lgr5) expressing epithelial stem cells that are capable of differenti-
ating into the various sub-lineage found in the gut, including ente-
rocytes, goblet cells, enteroendocrine cells, tuft cells, Paneth cells,
and M cells (9). Signals received depending on micro-anatomic
location and neighboring cells can determine lineage specificity.
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It has been shown that stromal cells in the subepithelial dome
of the FAE provide RANKL to RANK-expressing stem cells to
induce M cell differentiation, and that in RANKL-deficient mice,
M cells fail to develop unless sufficient exogenous RANKL is pro-
vided (57, 72). This data demonstrated an absolute requirement
for RANK signaling during M cell development. This work further
suggested that RANK signaling on M cell precursors is triggered
by membrane-bound RANKL on stromal cells, such that cell–cell
contact and FAE micro-architecture may be critical to M cell dif-
ferentiation (57). RANKL has been shown to specifically induce
the markers annexin A5 and myristoylated alanine-rich C-kinase
substrate)-like protein 1 (MARCKS) on M cell precursor stem cells,
but their significance in this context remains unclear (9, 73, 74).
RANK signaling apparently acts in a critical manner to upreg-
ulate the ETS (E26 transformation-specific) transcription factor
Spi-B, which was shown to be required for M cell maturation,
and is responsible for cell-intrinsic expression of genes including
glycoprotein 2 (Gp2), TNF alpha-induced protein 2 (Tnfaip2),
and C–C motif chemokine ligand 9 (Ccl9) (73, 74). Finally, it
remains to be determined why only a small proportion of Lgr5+
stem cells in the subepithelial dome of the FAE develop into stem
cells despite ample exposure to stromal RANKL (9, 57). A possi-
bility recently put forward might involve cross-talk between the
RANK and Notch signaling pathways during M cell development,
such that availability of given Notch ligands to M cell precur-
sors determines whether RANK signaling is sufficient for M cell
differentiation to proceed (9, 75).
BONE HOMEOSTASIS
Bone is essential for providing skeletal strength, vital organ pro-
tection, a mineral reservoir for calcium, and a site for immune
cell development. Bone cell homeostasis is maintained by the bal-
anced functions of primarily two cell-types: OBs, which build
bone, and OCs, which resorb bone (76, 77). In a continuous
cycle, OCs remove bone by sealing off sections and secreting diges-
tive acid into the lacunae, followed by OBs filling the cavity with
new bone (76, 77). This constant remodeling of the bone matrix
is necessary to maintain both skeletal strength and a reservoir
for hematopoiesis. There is intense interest in understanding the
mechanisms governing OC development and function. While OBs
are mesenchymal lineage cells,OCs arise from myeloid hematopoi-
etic precursor cells (76, 77). Interestingly, new OCs are generated
largely through cell contact-dependent interactions between OC
precursors and OBs in the bone stroma (76, 77). RANKL–RANK
signaling was shown early on to be a potent driver of OC differen-
tiation even under minimal in vitro conditions (5). OC precursors
require the growth factor M-CSF for OC precursor growth and
RANK induction (78, 79), and then the RANK-induced tran-
scription factors c-fos (80), NFATc1/NFAT2 (44, 46), and NF-κB
members p50 and p52 (81, 82) [which also activated c-fos and
NFATc1/NFAT2 in pre-OCs (83)] for OC development. Mice
genetically deficient for any of these factors exhibit osteopetro-
sis, a thickening of the bones, due to reduced OC numbers and/or
activity. RANKL–RANK-mediated activation of these pathways
and induction of c-fos, NFATc1/NFAT2, and canonical and non-
canonical NF-κB pathways during OC development is necessary
for activation of OC-critical genes, including tartrate-resistant acid
(TRAP), cathepsin-K, calcitonin receptor, as well as c-myc, to pro-
mote OC proliferation (76). RANKL–RANK signaling also plays a
crucial role in the bone-resorbing function of mature OCs, which
after αVβ3-mediated attachment of OCs to bone surfaces, leads
to activation of Src-dependent pathways, including Syk, through
complex formation involving RANK, Slp-76, Vav3, and Rac (76).
Activation of these pathways and cytoskeletal rearrangements
promote ruffled border formation via fusions between lysoso-
mal secretory vesicles and the cytoplasmic membrane (76, 84).
RANKL-deficient mice are severely osteopetrotic due to a cell non-
autonomous defect in OC development, and additionally exhibit
failed tooth eruption (common in developmental osteopetrosis),
and diversion of hematopoiesis to the spleen and liver due to
failed bone marrow cavity formation (58). Therefore, new bone
formation occurs in the absence of RANK signaling, including
intramembranous and endochondral ossification processes dur-
ing fetal development, but bone remodeling is severely diminished.
Further, RANK- and RANKL-deficient mice are exact phenocopies
with respect to OC development, suggesting an exclusive rela-
tionship between the RANK–RANKL receptor–ligand pair (55).
The critical source(s) of RANKL during normal bone remodel-
ing is still debated, but evidence suggests that the source changes
over development, such that hypertrophic chondrocytes provide
RANKL for removal of trabecule during endochondral ossifica-
tion, and trabecular osteocytes provide most RANKL for both
mature bone remodeling and in response to mechanical stress (85,
86). Additionally, many well known osteotropic factors, includ-
ing IL-1, IL-6, and IL-11 are believed to exert osteoclastogenic
activity simply by inducing RANKL expression on OBs (78). The
cytokine TNF-a promotes osteoclastogenesis, not only via direct
stimulation of OC precursors (87), but also by inducing RANKL
expression on stromal cells and RANK expression on OC precursor
cells (88). TRAF6-deficient mice also exhibit severe osteopetrosis,
confirming the critical relationship between this signaling adapter
and RANK signaling (28, 29). Another study examining TRAF
binding site in the RANK receptor suggests that TRAF6 might be
most important for OC function and normal F-actin ring for-
mation, and implying that signals through other TRAFs may also
make important contributions to RANK-mediated osteoclastoge-
nesis (89). However, a study using TRAF2-deficient OC precursors
showed that while TRAF2 made a minor contribution to RANK
signaling, it is primarily required for TNF-a-dependent osteoclas-
togenesis (90). Downstream of TRAF6, RANK signaling in OCs
has been shown to activate JNK1 (91), Akt/PKB (41), p44/42 ERK
(41), p38 MAPK (92), and the canonical NF-κB pathway (26).
RANK-mediated activation of the c-src pathway links it to a crit-
ical requirement c-src for normal OC development (40, 41, 93,
94). Studies of OC differentiation have also identified a critical
costimulatory pathway for RANK signaling involving immunore-
ceptor tyrosine based activation motif (ITAM)-containing recep-
tors DNAX activation protein of 12 kDa (DAP12) and Fc-receptor
g subunit (FcRg) (95). This costimulatory pathway is required
for RANK-mediated osteoclastogenesis, and signals downstream
through the protein kinase Syk (96, 97), which activates phospholi-
pase Cg (PLCg) and the BTK and Tec kinases (98), eventually lead-
ing to calcium-mediated activation of NFATc1/NFAT2 (95). OPG
functions as a soluble decoy-like factor for RANKL, and thus as a
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negative regulator of RANK signaling, and is capable of inhibit-
ing osteoclastogenesis in vitro, and of inducing osteoporosis when
transgenically overexpressed in mice (47). Furthermore, OPG-
deficient mice are described as osteoporotic, with excessive num-
bers of OCs (99). OPG has further been shown to inhibit mature
OC function in vitro (100). In addition to OPG, other negative reg-
ulatory mechanisms of RANK signaling have been described that
inhibit osteoclastogenesis. For instance, though T cells can express
RANKL, there is a negative correlation between T lymphocyte
activation and signaling through RANK on OC precursors, as T
cell-derived IFN-g drives proteasomal degradation of TRAF6 (42).
In this way, a productive immune response is prevented from hav-
ing an overlapping, deleterious effect on bone in the surrounding
environment. TRAF6 activates downstream signaling via non-
degradative ubiquitination (101). It has been demonstrated that
TRAF6-mediated RANK signaling in pre-OCs is negatively regu-
lated de-ubiquitinase CYLD, and that CYLD-deficient mice exhibit
osteoporosis due to increased OC activity (36). Another regulatory
mechanism involves negative feedback via by RANK-mediated
upregulation of IFN-b, which mediates a feedback mechanism
that blocks further c-fos-dependent activity (102). In support, it
is reported that c-fos-deficient OC precursors exhibit deficient
RANKL-mediated IFN-b production, and that mice deficient for
the IFNa/b receptor (IFNAR1) exhibit osteoporosis characterized
by an increase in OCs (102). A more recently characterized neg-
ative regulatory mechanism of RANK signaling in OC precursor
cells involves the formation of a TRAF3-containing complex on
the RANK intracellular domain that inhibits both canonical and
non-canonical NF-κB pathways (43, 103). The physiologic rele-
vance of this complex is demonstrated by TRAF3 conditionally
deficient mice, which exhibit mild osteoporosis (43). Finally, an
example of negative regulation of RANK-mediated ITAM activa-
tion has recently been described, which involves semaphorin 3A
(Sema3A) interaction with neuropilin-1, and is supported by the
finding that Sema3a-deficient mice are osteopenic (104). These
data highlight the multiple levels of control that bone requires
for proper homeostatic function, and suggest the potential that
RANKL signaling has as a therapeutic target in treating bone-
related ailments. In fact, denosumab, an anti-RANKL antibody is
now in clinics for use in treating osteoporosis and shows promise
for treating additional OC-related conditions (105).
INHERITED BONE DISEASES
Though typically rare, various heritable mutations linked to the
bone pathologies have been identified in the genes encoding the
RANKL–RANK–OPG system. Familial expansile osteolysis (FEO)
and Paget’s disease are rare autosomal dominant conditions char-
acterized by enhanced bone remodeling and osteolytic lesions
present in the long bones. Short in-frame duplications in exon
1 of the gene encoding RANK have been linked to FEO and Paget’s
disease of the bone (PDB) (106). It has been shown that these
mutations disrupt function of the RANK signal peptide and result
in constitutive RANK activity (106). Expansile skeletal hyper-
phosphatasia (ESH) is a genetic disorder characterized by early
onset deafness, premature loss of teeth, progressive hyperostotic
widening of long bones causing painful phalanges in the hands,
accelerated bone remodeling, and episodic hypercalcemia. While
ESH is distinguished phenotypically from FEO by the presence of
hypercalcemia and the absence of large osteolytic lesions with cor-
tical thinning in major long bones, it appears also to occur from
an activating mutation – in this case a 15-bp tandem repeat –
in the region encoding the RANK signal peptide (107). Multiple
additional mutations have been characterized in the gene encod-
ing RANK that result in varied forms of osteopetrosis, but despite
early onset, it has been shown in some cases that disease can be
cured by hematopoietic stem cell transplant even when carried
out in late infancy (108). Juvenile Paget’s disease is a rare autoso-
mal recessive bone disease in which children are normal at birth,
but then experience rapidly remodeling woven bone, osteope-
nia, fractures, and progressive skeletal deformity. Genetic analysis
determined that this disorder is the result of an inactivating muta-
tion in the gene encoding OPG, and that serum levels of OPG
are undetectable in affected individuals (109). Cherubism is a rare
autosomal dominant disease of the lower jaw characterized by
excessive OC-mediated bone resorption and associated with muta-
tions in the gene Sh3bp2 (110). While the mechanism(s) disease
onset was not initially understood, more recent work has demon-
strated that the mutations appear to impact regions of scaffolding
protein encoded by Sh3bp2 that coordinate signals converging
from RANK and M-CSFR to activate Syk, PLCg2, and Vav (111).
These alterations in signaling complexes lead to increased TNF-
a expression and augmented OC activity (111). Together these
genetic cases confirm the critical role of the RANKL–RANK–OPG
system in human bone development and function.
ACQUIRED BONE PATHOLOGIES
Much more common than bone pathologies caused directly by
genetic lesions to the RANKL–RANK–OPG systems are bone-
related pathologies that arise later due to environmental factors,
homeostatic dysregulation, hormonal changes, or other disease
sequelae. The most common of these is post-menopausal osteo-
porosis, a skeletal disorder characterized by weakening of the
bones and predisposition to fracture due to bone loss caused by
an imbalance in OC activity versus new bone formation (112,
113). Osteoporosis is associated with hormonal changes, such as
decreased estrogen levels in post-menopausal women, and has
been linked to increased RANKL levels on bone marrow cells
of women exhibiting osteoporosis (113, 114). Similarly, patients
receiving hormone ablation therapy for breast cancer (estrogen
suppression) or prostate cancer (chemical or surgical castration
for testosterone suppression) may also suffer osteoporotic bone
loss due to increased RANKL expression (112, 113). These findings
correlate with the osteoporotic phenotype observed in the OPG-
deficient mouse model, in which RANKL–RANK interactions are
enhanced due to the absence of the OPG-mediated inhibition
(99). Cancer is another area where the RANKL–RANK–OPG sys-
tem may affect bone health. In patients with bone metastases,
skeletal complications caused by increased OC activity may result
in pathological fractures, spinal cord compression, and the need
for radiotherapy to the bone or orthopedic surgery [collectively
known as skeletal-related events (SREs)] (115). Increased bone
turnover may even enhance tumor growth in bone by facili-
tating the early establishment, as well as later progression, of
bone metastases (116). Cancer metastases to bone result from
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engagement by tumor cells with non-malignant resident cells of
the bone microenvironment, including OCs, stromal cells, and
vascular cells, through cell–cell, paracrine, and/or endocrine inter-
actions. The role of RANKL–RANK–OPG in metastasis can be
divided into its contribution to enhanced osteolysis and to its
effects on promoting metastasis. In the former case, some exam-
ples and mechanisms have been described. For instance, bone pain
and excessive OC activity are the primary complication for mul-
tiple myeloma patients, with increased levels of RANKL often
found in bone stromal cells (117). With respect to mechanisms
of tumor-driven increases in RANK activity, one study showed
tumor cell expression of metalloproteases ADAMTS1 and MMP1,
factors associated with increased risk of metastasis in breast can-
cer, alter secretion of epidermal growth-like factors in a manner
that suppresses OPG expression by resident OBs (118). In another
study, it was shown that prostate cancer cells expressing a solu-
ble form of RANKL could directly induce osteoclastogenesis from
precursor cells in the absence of stromal accessory cells (119).
With respect to promoting metastasis, interest in a potential role
for RANKL–RANK was triggered by observations relating to its
role in epithelial organogenesis, specifically mammary stem cell
development, which could be envisioned as contributing to car-
cinogenic events (65, 115, 120). During tumor formation, RANKL
is found to increase proliferation and survival of both normal
and pre-neoplastic breast in addition to expansion of mammary
stem/progenitor cells (65, 120). Progesterone and prolactin, which
have been implicated in mammary tumorigenesis, both trigger
RANKL expression in the mammary gland (121). In one study
using a hormone-triggered mammary tumor model in mice, spe-
cific deletion of RANK in mammary epithelial cells significantly
delays tumor onset (65, 121). Further, RANKL treatment is shown
to protect mammary epithelial cells from γ-irradiation-induced
cell death, one indicator of malignancy (65, 121). In a complemen-
tary study, transgenic mammary gland overexpression of RANK
was shown to exacerbate medroxyprogesterone acetate-induced
mammary tumor formation, and that systemic RANKL block-
ade resulted in a 90% reduction in hormone-induced mammary
tumor onset (120, 121). With respect to showing the contribution
of local differentiation factors, in addition to chemotactic fac-
tors, to metastasis, it was shown that RANKL stimulation directly
triggered metastasis of melanoma cell lines and breast cancer in
patients in a manner that is independent of pro-osteoclastic activ-
ity (122). A study investigating sources of RANKL outside of bone
that may trigger metastasis showed that pulmonary metastasis of
breast cancer may be driven by RANKL expressed on infiltrating
Tregs, implicating the role of inflammatory factors in RANKL-
driven metastasis (123). Finally, important work to determine
the key molecular pathways downstream of RANK signaling in
metastatic tumor cells showed a correlation between metastatic
potential and RANK-induced IKK-a activation (124).
IMMUNITY AND OSTEOIMMUNOLOGY
The RANKL–RANK–OPG system was initially discovered through
multiple independent efforts, some interested in discovering new
genes relevant to bone biology, and others initially focused on
the immune system. As such, while initial efforts to characterize
the role of RANKL–RANK–OPG in controlling osteoclastogenesis
were ongoing, parallel efforts were underway showing that RANKL
provided by T cells can significantly enhance immunity by promot-
ing the survival and function of DCs, the most potent professional
antigen-presenting cells, in the context of an immune response
(4, 125, 126). Emerging understanding that key cellular regula-
tors of the immune and bone systems were responsive to the
same cytokine systems and derived from common progenitors
(127) was one of the key impetuses in developing a new field
of study, osteoimmunology, which seeks to examine the interac-
tions between the bone and immune systems. Studies of RANK
intracellular signaling pathways and regulatory mechanisms have
further demonstrated the extent to which bone and immune cells
overlap in these areas. Osteoimmunologic mechanisms are rele-
vant to diseases including RA, periodontal disease, osteoporosis,
osteoarthritis, multiple myeloma, and metastatic bone tumors,
all of which are associated with bone breakdown (128). The
most prominently studied example of the pathologic relationship
between bone and immune cells is RA, but many RANKL–RANK–
OPG-driven mechanisms of pathologic bone–immune cell inter-
action are common between different diseases (129) (depicted in
Figure 2). RA is an autoimmune disease that is characterized by
inflammation of the synovial joints, leading to severe structural
damage including bone destruction. RANKL is highly expressed
in the synovium of RA patients and is largely responsible for RA-
related bone destruction (129). The source of pathogenic RANKL
in RA synovium is still debated, as T cells may express high levels,
but the osteoclastogenic action of T cells can be counteracted by
IFN-g production (42). Instead, it appears that synovial fibrob-
lasts are the primary RANKL source in RA (42). It has further
been determined that Th17 helper T cells are responsible for
inducing RANKL expression on synovial fibroblasts via expres-
sion of IL-17 as well as IL-1, TNF-a, and IL-6 (129). At the same
time, a recent fate mapping study showed that more a potently
osteoclastogenic version of pathogenic Th17 cells are those that
were previously Foxp3-expressing Tregs, but that converted phe-
notypes, and gained RANKL expression in response to synovial
fibroblast-derived IL-6 (130). Another study suggests that OC dif-
ferentiation activity may not be the only function of RANKL in
bone–immune cell interactions. Multi-photon microscopy was
employed to perform intravital imaging of bone tissue in the
context of RANKL-mediated OC activation, and it was showed
that RANKL-expressing Th17 cells were able to stimulate mature
but non-resorptive OCs to begin resorbing bone, suggesting that
Th17-mediated bone pathology may not necessarily generate need
OCs, but simply increase activity of mature resident OCs (131). In
another model system, a recent study showed that RANKL expres-
sion by B cells drive OC formation in an ovariectomy (ovx) model
of osteoporosis, suggesting that B cells should be examined more
closely in bone–immune cell interactions (132). For normal bone
remodeling, OB or bone stromal cells have long been considered
the major sources of RANKL, but recent work employing cell-
specific RANKL deletion suggests that osteocytes are in fact the
critical providers of RANKL to OC precursors (86, 133). It is
therefore clear that the cellular source of RANKL is critical to
the context in which it is acting, and whether it primarily affects
bone or immune cells. In addition to activating the immune system
through RANK signaling on DCs, RANKL is conversely important
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FIGURE 2 | Osteoimmunology and RANKL–RANK–OPG.
Osteoimmunology involves cross-regulation between cells of the bone and
immune systems, and in some cases in the source of pathogenic
conditions like rheumatoid arthritis (RA). The interface between the
synovium and bone joints is where RA occurs, and where many cellular
interactions typical of osteoimmunity have been characterized. The unifying
characteristic of many of these cellular interactions is often the interplay
between sources of RANKL and RANK-expressing cells. Secondarily, there
are factors secreted or provided through cell contact that promote RANKL
and/or RANK expression. The net effect of osteoimmune interactions is
largely tallied according to increased (or regulation of) bone loss due to
enhanced RANKL-mediated osteoclast (OC) differentiation from pre-OCs.
In addition to the usual sources of RANKL available to pre-OCs from
bone-associated cells including bone stromal cells, osteoblasts (OBs), and
osteocytes, an inflammatory environment provides other sources. B cells
activated by TLR ligands, such as LPS, and expanded by T cell help induce
RANKL expression. T cells, which are activated by dendritic cells (DCs)
through MHC/Antigen (Ag)–TCR interactions, can also express RANKL,
which can both act on pre-OCs, but can also act on DCs to promote their
survival and to prolong T–DC interactions. DC interactions with helper T
cells influence their differentiation into subsets such as Th1, Th2, and Th17.
Th1 and Th2 cell elaboration of IFNγ and IL-4, respectively, exhibit
modulating effects on RANK-mediated osteoclastogenesis. However, IL-17
produced by Th17 cells can act to induce RANKL, especially by synovial
fibroblasts under inflammatory conditions. Synovial macrophages may also
enhance fibroblast expression of RANKL through secretion of
inflammatory cytokines like IL-1, IL-6, and TNF-α. At the same time,
mitigation of potentially deleterious effects of osteoimmune interactions
may be provided by secretion of OPG, which attenuates the potency of
available RANKL.
for inducing immune tolerance by promoting Treg differentiation
in certain autoimmune contexts. RANKL is required for Tregs
that prevent cytotoxic destruction of pancreatic beta islet cells in a
mouse type-1 diabetes model (134), as well as for Treg-mediated
control of a colitis model (135). RANKL may promote periph-
eral immune tolerance. For instance, it has been reported that
RANKL-expressing keratinocytes in inflamed skin trigger epider-
mal DCs to induce a Treg phenotype in infiltrating T cells (136).
At the same time, another autoimmune disorder has recently been
revealed, at a clinical level, to harbor a deleterious role for RANKL.
High serum levels of soluble RANKL apparently correlate with risk
for development of type-2 diabetes mellitus (T2DM). A recent
study has identified a mechanism underlying this risk factor as
hepatic insulin resistance induced by the RANK–NF-κB signaling
pathway (137). Blockade of hepatic RANKL was able to ameliorate
disease and lower plasma glucose levels, highlighting a potential
strategy for treating T2DM (137). Finally, an example of modula-
tion of RANKL function at the level of central immune tolerance
may have important clinical implications. It was recently shown
that mTEC inhibition via blockade of RANKL may represent a
viable approach to boosting anti-tumor T cell responses by tem-
porarily disrupting thymic negative selection to TSAs expressed
by tumors (138). Together these examples show that RANKL–
RANK either activating or suppressive to an immune response
depending on the context, and that while important roles for
other cytokines have been identified [e.g., IL-1, IL-6, IL-17, IL-
23, TNF-a, and TGF-b (129)], RANKL remains the most critical
means of communication between cells of the osteoimmunologic
network.
CONCLUDING REMARKS AND FUTURE DIRECTIONS
It is difficult to overstate the importance of the discovery of the
RANKL–RANK–OPG system with respect to understanding how
bone homeostasis is controlled. The hundreds of studies it spurred
have uncovered a much more vast biological network of regulation
involving RANKL–RANK in and across other organ systems, and
have as an additional benefit, demonstrated previously unknown
ways in which organ systems interact and cross-regulate at a
molecular level. Now that RANKL–RANK has been successfully
harnessed for purposes of therapeutic treatments of osteoporosis,
bone loss, and bone metastasis, it will be important to answer addi-
tional questions – specifically with respect to how RANK signaling
is modulated, and how and on what cells RANKL is physiologically
expressed under normal versus disease conditions – if therapeutic
RANKL–RANK targeting is to be refined and potentially applied
to additional disease conditions.
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